Since about 1970 scalp cooling has been used to prevent chemotherapy-induced hair loss, one of the most common and emotionally distressing side effects of cancer therapy. Generally accepted opinions, uncertainty and controversy, topics to study and recommendations for improving the results of scalp cooling are the subjects of this article which was also presented at the MASCC Symposium, June 2003, Berlin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-003-0551-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fucoidan treats chemotherapy-induced alopecia and helps cyclophosphamide treat tumors.
Int J Biol Macromol
December 2024
College of Chemical Engineering, Huaqiao University, Xiamen, Fujian 361021, China; Xiamen Engineering and Technological Research Center for Comprehensive Utilization of Marine Biological Resources, Xiamen 361021, China.
Chemotherapy-induced alopecia (CIA) represents one of the most common side effects of cancer treatment. Currently, scalp cooling systems are utilized to treat CIA, but their safety and effectiveness remain limited. The objective of this study was to investigate the effect of fucoidan on CIA and to elucidate the possible mechanism of fucoidan in treating CIA.
View Article and Find Full Text PDFScalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers-an Asian tertiary institution experience.
Support Care Cancer
November 2024
Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore.
Purpose: Scalp cooling therapy (SCT) improves chemotherapy-induced alopecia (CIA), but there are few published data about its efficacy in an Asian-predominant population. We report our tertiary institution experience of SCT in patients with breast or gynaecological cancers undergoing chemotherapy.
Methods: The Paxman scalp cooling system was employed for eligible women with breast or gynaecological cancers receiving anthracycline or taxane-based chemotherapy.
tDCS and local scalp cooling do not change corticomotor and intracortical excitability in healthy humans.
Clin Neurophysiol
December 2024
Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil.
Article Synopsis
- The study aimed to determine if scalp cooling can enhance the effects of transcranial direct current stimulation (tDCS) on motor cortex excitability.
- It involved 105 healthy participants in a randomized, double-blind design where various tDCS protocols and scalp cooling were tested, with motor evoked potentials measured to assess changes in brain excitability.
- Results indicated that neither tDCS nor scalp cooling produced measurable improvements in motor cortex excitability, suggesting that these methods do not alter cortical excitability effectively.
Therapeutic Effect of Superficial Scalp Hypothermia on Chemotherapy-Induced Alopecia in Breast Cancer Survivors.
J Clin Med
September 2024
Heat Pipe and Thermal Management Research Group, College of Engineering, Design and Physical Sciences, Brunel University, London UB8 3PH, UK.
Article Synopsis
- - Alopecia is a common side effect of chemotherapy for early breast cancer, with over 40% of patients experiencing permanent hair loss, impacting their body image and quality of life, leading some to refuse treatment.
- - Scalp cooling has proven to be the most effective strategy to reduce chemotherapy-induced alopecia (CIA), cutting the incidence of significant hair loss by 50% without major risks to patient survival.
- - There is a need for more research on CIA due to inconsistencies in study methods; developing standardized assessment techniques and improving preclinical models could enhance understanding and treatment options.
Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention.
Curr Oncol
September 2024
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Docetaxel is a commonly used taxane chemotherapeutic agent in the treatment of a variety of cancers, including breast cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, gastric cancer, and head and neck cancer. Docetaxel exerts its anti-cancer effects through inhibition of the cell cycle and induction of proapoptotic activity. However, docetaxel also impacts rapidly proliferating normal cells in the scalp hair follicles (HFs), rendering the HFs vulnerable to docetaxel-induced cell death and leading to chemotherapy-induced alopecia (CIA).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!